CÔNG TY CỔ PHẦN DƯỢC PHẨM MEDBOLIDE

GLIGCA REPORT AT THE PHARMACY DEPARTMENT - FV HOSPITAL

On November 2, 2023, Medbolide Joint Stock Company held a product reporting session for GLIGCA 25 (Milnacipran HCl 25 mg) a chronic pain treatment drug at the Department of Pharmacy - FV Hospital. The report was chaired by Doctor Nguyen Nam Binh (Treatment Doctor at the Pain Treatment Center - FV Hospital) and had the participation of more than 40 clinical pharmacists.

Dr. Nguyen Nam Binh presented chronic pain mechanisms, recommendations, and clinical research proving that Milnacipran has high clinical effectiveness. In particular, GLIGCA does not cause cognitive impairment, does not cause weight gain and is well tolerated, making it easy for patients to comply with treatment. GLIGCA is an effective pain relief solution in the treatment of chronic pain and FM (Fibromyalgia syndrome).

After the report, Dr. Nguyen Nam Binh and the doctors had many interesting discussions about the usage, safety and need to use the drug GLIGCA at the Pain Treatment Center - FV Hospital. Medbolide Company would like to thank the reporter and hopes to continue to accompany the Hospital in bringing effective chronic pain treatment solutions and improving the quality of life for chronic pain patients.

Pic 1
Pic 2
Pic 3
Readers comments